Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ABBV NYSE:GSK NYSE:NVO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$194.61+2.1%$187.10$163.81▼$218.66$344.93B0.486.28 million shs3.72 million shsGSKGSK$39.63+1.5%$38.98$31.72▼$44.67$81.24B0.54.95 million shs4.96 million shsNVONovo Nordisk A/S$71.17+2.1%$70.25$57.00▼$143.49$318.53B0.647.28 million shs5.05 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie+0.60%-0.02%+0.85%+9.75%+13.46%GSKGSK+1.43%+1.35%-4.45%+16.04%+1.11%NVONovo Nordisk A/S+0.24%-0.01%-7.49%+14.21%-50.29%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABBVAbbVie4.7974 of 5 stars2.45.03.33.94.01.71.3GSKGSK2.3783 of 5 stars1.14.02.50.02.70.02.5NVONovo Nordisk A/S4.7997 of 5 stars4.15.02.50.03.50.03.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABBVAbbVie 2.81Moderate Buy$211.298.57% UpsideGSKGSK 2.11Hold$37.38-5.68% DownsideNVONovo Nordisk A/S 2.27Hold$112.0057.37% UpsideCurrent Analyst Ratings BreakdownLatest ABBV, NVO, and GSK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025ABBVAbbVieCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold$205.006/9/2025ABBVAbbVieBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold$204.006/3/2025GSKGSKBerenberg BankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold5/14/2025ABBVAbbVieCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$210.00 ➝ $205.005/8/2025ABBVAbbVieBNP ParibasSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold4/29/2025ABBVAbbVieGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$214.00 ➝ $216.004/28/2025ABBVAbbVieEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$204.00 ➝ $205.004/28/2025ABBVAbbVieMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$241.00 ➝ $250.004/28/2025GSKGSKHsbc Global ResSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong Sell4/28/2025NVONovo Nordisk A/SHsbc Global ResSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/25/2025NVONovo Nordisk A/SDbs BankSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeSell(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABBVAbbVie$56.33B6.10$15.31 per share12.71$1.90 per share102.43GSKGSK$40.10B2.02$5.74 per share6.90$8.07 per share4.91NVONovo Nordisk A/S$303.14B1.05$3.99 per share17.85$4.66 per share15.27Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABBVAbbVie$4.28B$2.3583.1013.921.287.31%412.03%13.11%7/31/2025 (Estimated)GSKGSK$3.29B$1.9420.458.521.559.89%48.82%11.15%7/30/2025 (Estimated)NVONovo Nordisk A/S$14.64B$3.3821.1115.271.3634.52%80.94%24.23%8/6/2025 (Estimated)Latest ABBV, NVO, and GSK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025 NVONovo Nordisk A/S$0.89N/AN/AN/A$77.51 billionN/A7/30/2025Q2 2025GSKGSK$1.12N/AN/AN/A$7.92 billionN/A7/24/2025Q2 2025ABBVAbbVie$3.24N/AN/AN/A$14.93 billionN/A5/7/2025Q1 2025NVONovo Nordisk A/S$0.92$0.92N/A$0.92N/A$11.87 billion4/30/2025Q1 2025GSKGSK$1.08$1.13+$0.05$1.00$7.52 billion$10.06 billion4/25/2025Q1 2025ABBVAbbVie$2.40$2.46+$0.06$0.72$12.91 billion$13.34 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABBVAbbVie$6.563.37%N/A279.15%53 YearsGSKGSK$1.694.26%N/A87.11%N/ANVONovo Nordisk A/S$1.632.29%N/A48.22%N/ALatest ABBV, NVO, and GSK DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date6/20/2025ABBVAbbViequarterly$1.643.54%7/15/20257/15/20258/15/20255/2/2025GSKGSKquarterly$0.42164.1%5/16/20255/16/20257/10/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABBVAbbVie44.140.760.64GSKGSK1.210.870.58NVONovo Nordisk A/S0.700.740.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABBVAbbVie70.23%GSKGSK15.74%NVONovo Nordisk A/S11.54%Insider OwnershipCompanyInsider OwnershipABBVAbbVie0.25%GSKGSK10.00%NVONovo Nordisk A/S0.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABBVAbbVie55,0001.77 billion1.76 billionOptionableGSKGSK68,6292.05 billion1.84 billionOptionableNVONovo Nordisk A/S77,3494.47 billion4.46 billionOptionableABBV, NVO, and GSK HeadlinesRecent News About These CompaniesNovo Nordisk A/S (NYSE:NVO) Shares Up 2.8% - Should You Buy?3 hours ago | marketbeat.comEuropean Medicines Agency Gave Positive Opinion on Novo Nordisk’s (NVO) Ozempic LabelJuly 10 at 9:37 AM | msn.comFinancial Gravity Asset Management Inc. Takes Position in Novo Nordisk A/S (NYSE:NVO)July 10 at 9:09 AM | marketbeat.comMoloney Securities Asset Management LLC Raises Stock Holdings in Novo Nordisk A/S (NYSE:NVO)July 10 at 7:15 AM | marketbeat.comNovo Nordisk Receives Boost on $2.34B Italian FactoryJuly 9 at 11:36 PM | msn.comIIMA, Novo Nordisk India sign pact to tackle obesity using multi-pronged collabJuly 9 at 11:36 PM | indianexpress.comI3 Reasons I Bought Novo Nordisk Stock Instead of Eli LillyJuly 9 at 6:16 PM | fool.comIs Novo Nordisk Increasing Dosage to Defend Wegovy's Edge in Obesity?July 9 at 12:50 PM | zacks.comNovo Nordisk A/S (NYSE:NVO) Shares Sold by Main Street Research LLCJuly 9 at 10:33 AM | marketbeat.comHims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapsesJuly 9 at 9:00 AM | cnbc.comChemung Canal Trust Co. Decreases Stake in Novo Nordisk A/S (NYSE:NVO)July 9 at 8:37 AM | marketbeat.comValeo Financial Advisors LLC Reduces Stock Holdings in Novo Nordisk A/S (NYSE:NVO)July 9 at 6:46 AM | marketbeat.comM&T Bank Corp Reduces Position in Novo Nordisk A/S (NYSE:NVO)July 9 at 6:46 AM | marketbeat.comNovo Nordisk: Reclaiming Market ShareJuly 9 at 5:04 AM | seekingalpha.comTD Cowen Keeps Buy on Novo Nordisk (NVO)July 9 at 2:11 AM | finance.yahoo.comNovo Nordisk Seeks Approval For Higher Wegovy Dose In EuropeJuly 8 at 3:43 PM | msn.comNovo Nordisk submits new Wegovy dose for EU approvalJuly 8 at 3:43 PM | msn.comNovo Nordisk A/S (NYSE:NVO) Shares Up 1.6% - Still a Buy?July 8 at 3:08 PM | marketbeat.comNovo Nordisk Seeks EU Approval for Higher Wegovy DoseJuly 8 at 10:36 AM | devdiscourse.comDNovo Nordisk Shares Edge Higher After Seeking EU Approval for Higher-Dose WegovyJuly 8 at 10:36 AM | msn.comNovo Nordisk submits higher Wegovy dose to the European Medicines Agency for approvalJuly 8 at 9:32 AM | reuters.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseRKLB Breakout Fails Near Highs: Should Investors Be Concerned?By Ryan Hasson | June 11, 2025View RKLB Breakout Fails Near Highs: Should Investors Be Concerned?ABBV, NVO, and GSK Company DescriptionsAbbVie NYSE:ABBV$194.61 +3.99 (+2.09%) As of 03:54 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.GSK NYSE:GSK$39.62 +0.59 (+1.50%) As of 03:54 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.Novo Nordisk A/S NYSE:NVO$71.17 +1.48 (+2.13%) As of 03:54 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Boeing's Rebound Is Well Underway—But Is It Too Late? Why Microsoft Keeps Showing Up in Congressional Portfolios Buffett's $2B+ Bet With Big Long-Term Potential Just Got Upgraded Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
